These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33593838)

  • 1. Nybomycin inhibits both types of
    Shiriaev DI; Sofronova AA; Berdnikovich EA; Lukianov DA; Komarova ES; Marina VI; Zakalyukina YV; Biryukov MV; Maviza TP; Ivanenkov YA; Sergiev PV; Osterman IA; Dontsova OA
    Antimicrob Agents Chemother; 2023 May; 95(5):. PubMed ID: 33593838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Landscape of Phenotypic and Transcriptional Responses to Ciprofloxacin in Acinetobacter baumannii: Acquired Resistance Alleles Modulate Drug-Induced SOS Response and Prophage Replication.
    Geisinger E; Vargas-Cuebas G; Mortman NJ; Syal S; Dai Y; Wainwright EL; Lazinski D; Wood S; Zhu Z; Anthony J; van Opijnen T; Isberg RR
    mBio; 2019 Jun; 10(3):. PubMed ID: 31186328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional Characterization of the DNA Gyrases in Fluoroquinolone-Resistant Mutants of Francisella novicida.
    Caspar Y; Siebert C; Sutera V; Villers C; Aubry A; Mayer C; Maurin M; Renesto P
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis.
    Pantel A; Petrella S; Matrat S; Brossier F; Bastian S; Reitter D; Jarlier V; Mayer C; Aubry A
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4524-9. PubMed ID: 21768507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of mutational patterns in quinolone resistance-determining regions of GyrA and ParC of clinical isolates.
    Ostrer L; Khodursky RF; Johnson JR; Hiasa H; Khodursky A
    Int J Antimicrob Agents; 2019 Mar; 53(3):318-324. PubMed ID: 30582984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fluoroquinolone resistance associated mutation in gyrA Affects DNA supercoiling in Campylobacter jejuni.
    Han J; Wang Y; Sahin O; Shen Z; Guo B; Shen J; Zhang Q
    Front Cell Infect Microbiol; 2012; 2():21. PubMed ID: 22919613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and virtual screening of novel fluoroquinolone analogs as effective mutant DNA GyrA inhibitors against urinary tract infection-causing fluoroquinolone resistant
    Balasubramaniyan S; Irfan N; Umamaheswari A; Puratchikody A
    RSC Adv; 2018 Jun; 8(42):23629-23647. PubMed ID: 35540291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Droplet Digital PCR-Based Detection and Quantification of GyrA Thr-86-Ile Mutation Based Fluoroquinolone-Resistant Campylobacter jejuni.
    Luo Y; Zhang W; Cheng Y; Lu Q; Guo Y; Wen G; Shao H; Cheng Z; Luo Q; Zhang T
    Microbiol Spectr; 2022 Apr; 10(2):e0276921. PubMed ID: 35412390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases.
    Black MT; Stachyra T; Platel D; Girard AM; Claudon M; Bruneau JM; Miossec C
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3339-49. PubMed ID: 18625781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WQ-3810: A new fluoroquinolone with a high potential against fluoroquinolone-resistant Mycobacterium tuberculosis.
    Ouchi Y; Mukai T; Koide K; Yamaguchi T; Park JH; Kim H; Yokoyama K; Tamaru A; Gordon SV; Nakajima C; Suzuki Y
    Tuberculosis (Edinb); 2020 Jan; 120():101891. PubMed ID: 31778929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
    Jorgensen JH; Weigel LM; Ferraro MJ; Swenson JM; Tenover FC
    Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study.
    Shigemura K; Tanaka K; Yamamichi F; Shirakawa T; Miyake H; Fujisawa M
    Int J Antimicrob Agents; 2012 Dec; 40(6):516-20. PubMed ID: 23068598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Molecular Genetics of Fluoroquinolone Resistance in Mycobacterium tuberculosis.
    Mayer C; Takiff H
    Microbiol Spectr; 2014 Aug; 2(4):MGM2-0009-2013. PubMed ID: 26104201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding.
    Mustaev A; Malik M; Zhao X; Kurepina N; Luan G; Oppegard LM; Hiasa H; Marks KR; Kerns RJ; Berger JM; Drlica K
    J Biol Chem; 2014 May; 289(18):12300-12. PubMed ID: 24497635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
    Fisher LM; Lawrence JM; Josty IC; Hopewell R; Margerrison EE; Cullen ME
    Am J Med; 1989 Nov; 87(5A):2S-8S. PubMed ID: 2574005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of amino acid substitutions in B subunit of DNA gyrase in Mycobacterium leprae on fluoroquinolone resistance.
    Yokoyama K; Kim H; Mukai T; Matsuoka M; Nakajima C; Suzuki Y
    PLoS Negl Trop Dis; 2012; 6(10):e1838. PubMed ID: 23071850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
    Kern G; Palmer T; Ehmann DE; Shapiro AB; Andrews B; Basarab GS; Doig P; Fan J; Gao N; Mills SD; Mueller J; Sriram S; Thresher J; Walkup GK
    J Biol Chem; 2015 Aug; 290(34):20984-20994. PubMed ID: 26149691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of DNA gyrase and topoisomerase IV mutations in fluoroquinolone resistance of Capnocytophaga spp. clinical isolates and laboratory mutants.
    Ehrmann E; Jolivet-Gougeon A; Bonnaure-Mallet M; Fosse T
    J Antimicrob Chemother; 2017 Aug; 72(8):2208-2212. PubMed ID: 28453633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
    Cambau E; Matrat S; Pan XS; Roth Dit Bettoni R; Corbel C; Aubry A; Lascols C; Driot JY; Fisher LM
    J Antimicrob Chemother; 2009 Mar; 63(3):443-50. PubMed ID: 19147516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.